Monte Rosa Therapeutics Debt-to-Equity Ratio Growth & History (GLUE)
Monte Rosa Therapeutics's debt-to-equity ratio was 0.17 for fiscal 2025.
View full Monte Rosa Therapeutics company overviewMonte Rosa Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.17 | −0.02 | −12.23% |
| 2024 | 2024-12-31 | 0.19 | −0.07 | −25.40% |
| 2023 | 2023-12-31 | 0.26 | 0.08 | +48.32% |
| 2022 | 2022-12-31 | 0.17 | 0.17 | — |
| 2021 | 2021-12-31 | 0.00 | — | — |
Monte Rosa Therapeutics quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.08 | −0.08 | −49.19% |
| Q1 2026 | 2026-03-31 | 0.07 | −0.08 | −50.81% |
| Q4 2025 | 2025-12-31 | 0.17 | −0.02 | −12.23% |
| Q3 2025 | 2025-09-30 | 0.16 | −0.05 | −23.18% |
| Q2 2025 | 2025-06-30 | 0.15 | −0.04 | −22.29% |
| Q1 2025 | 2025-03-31 | 0.15 | −0.14 | −48.64% |
| Q4 2024 | 2024-12-31 | 0.19 | −0.07 | −25.40% |
| Q3 2024 | 2024-09-30 | 0.21 | −0.04 | −15.41% |
| Q2 2024 | 2024-06-30 | 0.20 | −0.02 | −10.32% |
| Q1 2024 | 2024-03-31 | 0.30 | 0.11 | +56.40% |
| Q4 2023 | 2023-12-31 | 0.26 | 0.08 | +48.32% |
| Q3 2023 | 2023-09-30 | 0.25 | 0.09 | +60.31% |
| Q2 2023 | 2023-06-30 | 0.22 | 0.06 | +36.38% |
| Q1 2023 | 2023-03-31 | 0.19 | 0.17 | +1043.06% |
| Q4 2022 | 2022-12-31 | 0.17 | 0.17 | — |
| Q3 2022 | 2022-09-30 | 0.16 | — | — |
| Q2 2022 | 2022-06-30 | 0.16 | — | — |
| Q1 2022 | 2022-03-31 | 0.02 | — | — |
| Q4 2021 | 2021-12-31 | 0.00 | — | — |
Monte Rosa Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Monte Rosa Therapeutics's debt-to-equity ratio increased from 0.00 to 0.17, a change of 0.17. The latest reported quarter, Q2 2026, shows 0.08.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Monte Rosa Therapeutics source filings ↗